Contineum Phase 2 VISTA trial did not meet primary, secondary endpoints

Contineum (CTNM) Therapeutics reported topline data from its Phase 2 VISTA trial of PIPE-307, an M1 receptor antagonist, in development for the treatment of patients with relapsing-remitting multiple sclerosis. The trial demonstrated acceptable safety and tolerability at both doses. The trial did not meet its prespecified primary or secondary efficacy endpoints. In RRMS patients, no significant change was observed in binocular 2.5% low contrast letter acuity across treatment arms. The company continues to interrogate the trial data related to its exploratory endpoints. “We’re disappointed by these results, but are grateful to the VISTA trial investigators, and especially to the patients and their families,” said Timothy Watkins, M.D., M.Sc., Chief Medical Officer and Head of Development, Contineum Therapeutics. “We intend to learn from these data and remain committed to pursuing novel therapies for patients with inflammatory and fibrotic diseases.”